S
urgical aortic valve replacement increasingly uses bioprosthetic implants rather than mechanical valves. Because of this and the expanding indications for transcatheter heart valve therapies, the majority of patients undergoing an aortic valve replacement procedure will receive a pericardial tissue valve (1) . Owing to this considerable shift toward bioprosthesis implantation, it is expected that patients will increasingly present with degenerated bioprostheses over time. Structural valve deterioration can result in leaflet degeneration and failure, as evidenced by valve stenosis, regurgitation, or a combination of both (2) . Treatment of such patients remains a clinical challenge. Although reoperation is considered the standard of care, these patients are frequently elderly and repeat cardiac surgery is associated with a significant risk of morbidity and mortality. Transcatheter valve-invalve implantation has emerged as a promising alternative treatment option for patients at high surgical risk; however, it comes with its own complications and limitations (3) . Therefore, repair of a structurally degenerated bioprosthetic valve would be an intriguing causative therapy approach. 
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